Novel somatostatin receptor ligands therapies for acromegaly

Rosa Maria Paragliola, Roberto Salvatori

Research output: Contribution to journalReview article

Abstract

Surgery is considered the treatment of choice in acromegaly, but patients with persistent disease after surgery or in whom surgery cannot be considered require medical therapy. Somatostatin receptor ligands (SRLs) octreotide (OCT), lanreotide, and the more recently approved pasireotide, characterized by a broader receptor ligand binding profile, are considered the mainstay in the medical management of acromegaly. However, in the attempt to offer a more efficacious and better tolerated medical approach, recent research has been aimed to override some limitations related to the use of currently approved drugs and novel SRLs therapies, with potential attractive features, have been proposed. These include both new formulation of older molecules and new molecules. Novel OCT formulations are aimed in particular to improve patients' compliance and to reduce injection discomfort. They include an investigational ready-to-use subcutaneous depot OCT formulation (CAM2029), delivered via prefilled syringes and oral OCT that uses a "transient permeability enhancer" technology, which allows for OCT oral absorption. Another new delivery system is a long-lasting OCT implant (VP-003), which provide stable doses of OCT throughout a period of several months. Finally, a new SRL DG3173 (somatoprim) seems to be more selective for GH secretion, suggesting possible advantages in the presence of hyperglycemia or diabetes. How much these innovations will actually be beneficial to acromegaly patients in real clinical practice remains to be seen.

Original languageEnglish (US)
Article number78
JournalFrontiers in Endocrinology
Volume9
Issue numberMAR
DOIs
StatePublished - Mar 7 2018

Fingerprint

Somatostatin Receptors
Acromegaly
Octreotide
Ligands
Therapeutics
Syringes
Patient Compliance
Hyperglycemia
Permeability
Technology
Injections
Research
Pharmaceutical Preparations

Keywords

  • Acromegaly
  • Lanreotide
  • Octreotide
  • Pasireotide
  • Somatoprim
  • Somatostatin receptor ligands

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Novel somatostatin receptor ligands therapies for acromegaly. / Paragliola, Rosa Maria; Salvatori, Roberto.

In: Frontiers in Endocrinology, Vol. 9, No. MAR, 78, 07.03.2018.

Research output: Contribution to journalReview article

@article{a13c8083189544afb2ac8401596e983b,
title = "Novel somatostatin receptor ligands therapies for acromegaly",
abstract = "Surgery is considered the treatment of choice in acromegaly, but patients with persistent disease after surgery or in whom surgery cannot be considered require medical therapy. Somatostatin receptor ligands (SRLs) octreotide (OCT), lanreotide, and the more recently approved pasireotide, characterized by a broader receptor ligand binding profile, are considered the mainstay in the medical management of acromegaly. However, in the attempt to offer a more efficacious and better tolerated medical approach, recent research has been aimed to override some limitations related to the use of currently approved drugs and novel SRLs therapies, with potential attractive features, have been proposed. These include both new formulation of older molecules and new molecules. Novel OCT formulations are aimed in particular to improve patients' compliance and to reduce injection discomfort. They include an investigational ready-to-use subcutaneous depot OCT formulation (CAM2029), delivered via prefilled syringes and oral OCT that uses a {"}transient permeability enhancer{"} technology, which allows for OCT oral absorption. Another new delivery system is a long-lasting OCT implant (VP-003), which provide stable doses of OCT throughout a period of several months. Finally, a new SRL DG3173 (somatoprim) seems to be more selective for GH secretion, suggesting possible advantages in the presence of hyperglycemia or diabetes. How much these innovations will actually be beneficial to acromegaly patients in real clinical practice remains to be seen.",
keywords = "Acromegaly, Lanreotide, Octreotide, Pasireotide, Somatoprim, Somatostatin receptor ligands",
author = "Paragliola, {Rosa Maria} and Roberto Salvatori",
year = "2018",
month = "3",
day = "7",
doi = "10.3389/fendo.2018.00078",
language = "English (US)",
volume = "9",
journal = "Frontiers in Endocrinology",
issn = "1664-2392",
publisher = "Frontiers Media S. A.",
number = "MAR",

}

TY - JOUR

T1 - Novel somatostatin receptor ligands therapies for acromegaly

AU - Paragliola, Rosa Maria

AU - Salvatori, Roberto

PY - 2018/3/7

Y1 - 2018/3/7

N2 - Surgery is considered the treatment of choice in acromegaly, but patients with persistent disease after surgery or in whom surgery cannot be considered require medical therapy. Somatostatin receptor ligands (SRLs) octreotide (OCT), lanreotide, and the more recently approved pasireotide, characterized by a broader receptor ligand binding profile, are considered the mainstay in the medical management of acromegaly. However, in the attempt to offer a more efficacious and better tolerated medical approach, recent research has been aimed to override some limitations related to the use of currently approved drugs and novel SRLs therapies, with potential attractive features, have been proposed. These include both new formulation of older molecules and new molecules. Novel OCT formulations are aimed in particular to improve patients' compliance and to reduce injection discomfort. They include an investigational ready-to-use subcutaneous depot OCT formulation (CAM2029), delivered via prefilled syringes and oral OCT that uses a "transient permeability enhancer" technology, which allows for OCT oral absorption. Another new delivery system is a long-lasting OCT implant (VP-003), which provide stable doses of OCT throughout a period of several months. Finally, a new SRL DG3173 (somatoprim) seems to be more selective for GH secretion, suggesting possible advantages in the presence of hyperglycemia or diabetes. How much these innovations will actually be beneficial to acromegaly patients in real clinical practice remains to be seen.

AB - Surgery is considered the treatment of choice in acromegaly, but patients with persistent disease after surgery or in whom surgery cannot be considered require medical therapy. Somatostatin receptor ligands (SRLs) octreotide (OCT), lanreotide, and the more recently approved pasireotide, characterized by a broader receptor ligand binding profile, are considered the mainstay in the medical management of acromegaly. However, in the attempt to offer a more efficacious and better tolerated medical approach, recent research has been aimed to override some limitations related to the use of currently approved drugs and novel SRLs therapies, with potential attractive features, have been proposed. These include both new formulation of older molecules and new molecules. Novel OCT formulations are aimed in particular to improve patients' compliance and to reduce injection discomfort. They include an investigational ready-to-use subcutaneous depot OCT formulation (CAM2029), delivered via prefilled syringes and oral OCT that uses a "transient permeability enhancer" technology, which allows for OCT oral absorption. Another new delivery system is a long-lasting OCT implant (VP-003), which provide stable doses of OCT throughout a period of several months. Finally, a new SRL DG3173 (somatoprim) seems to be more selective for GH secretion, suggesting possible advantages in the presence of hyperglycemia or diabetes. How much these innovations will actually be beneficial to acromegaly patients in real clinical practice remains to be seen.

KW - Acromegaly

KW - Lanreotide

KW - Octreotide

KW - Pasireotide

KW - Somatoprim

KW - Somatostatin receptor ligands

UR - http://www.scopus.com/inward/record.url?scp=85043366712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043366712&partnerID=8YFLogxK

U2 - 10.3389/fendo.2018.00078

DO - 10.3389/fendo.2018.00078

M3 - Review article

C2 - 29563895

AN - SCOPUS:85043366712

VL - 9

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

SN - 1664-2392

IS - MAR

M1 - 78

ER -